Prothena Co. plc (NASDAQ:PRTA) Shares Acquired by Duncan Williams Asset Management LLC

Duncan Williams Asset Management LLC boosted its stake in Prothena Co. plc (NASDAQ:PRTA) by 41.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 69,199 shares of the biotechnology company’s stock after acquiring an additional 20,450 shares during the quarter. Duncan Williams Asset Management LLC’s holdings in Prothena were worth $958,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Orion Portfolio Solutions LLC raised its position in shares of Prothena by 4.4% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company’s stock worth $293,000 after purchasing an additional 739 shares during the last quarter. Pinnacle Associates Ltd. raised its holdings in shares of Prothena by 2.3% during the third quarter. Pinnacle Associates Ltd. now owns 125,747 shares of the biotechnology company’s stock valued at $2,104,000 after acquiring an additional 2,847 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Prothena by 3.8% in the third quarter. The Manufacturers Life Insurance Company now owns 86,071 shares of the biotechnology company’s stock valued at $1,440,000 after acquiring an additional 3,163 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Prothena by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 4,026 shares during the last quarter. Finally, Ensign Peak Advisors Inc increased its position in shares of Prothena by 30.4% during the second quarter. Ensign Peak Advisors Inc now owns 21,643 shares of the biotechnology company’s stock worth $447,000 after purchasing an additional 5,050 shares in the last quarter. Hedge funds and other institutional investors own 97.08% of the company’s stock.

Prothena Price Performance

PRTA stock opened at $15.62 on Friday. Prothena Co. plc has a 52-week low of $11.70 and a 52-week high of $33.84. The business has a fifty day moving average of $14.31 and a two-hundred day moving average of $17.95.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.08. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The firm had revenue of $0.97 million during the quarter, compared to the consensus estimate of $1.22 million. During the same period last year, the company earned $0.38 EPS. The company’s quarterly revenue was down 98.9% on a year-over-year basis. Sell-side analysts forecast that Prothena Co. plc will post -2.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on PRTA. HC Wainwright restated a “buy” rating and issued a $48.00 price objective (down previously from $84.00) on shares of Prothena in a report on Friday, December 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a research report on Monday, September 30th. StockNews.com downgraded shares of Prothena from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. Bank of America lowered their target price on Prothena from $26.00 to $22.00 and set a “neutral” rating on the stock in a report on Thursday, December 19th. Finally, Chardan Capital began coverage on Prothena in a research report on Friday, December 20th. They set a “buy” rating and a $40.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $46.50.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.